丹麦批准对4名与Ozempic和Wegovy有罕见眼病的病人提供赔偿。 Denmark approves compensation for four patients with rare eye condition linked to Ozempic and Wegovy.

丹麦已批准向四个人提供补偿,这些人患有由诺沃·诺迪斯克制造的与减重和糖尿病药物Ozempic和Wegovy有关的罕见的永久性眼病。 Denmark has approved compensation for four people who developed a rare, permanent eye condition linked to weight-loss and diabetes drugs Ozempic and Wegovy, made by Novo Nordisk. 丹麦病人赔偿协会向病人颁发了80万克朗(123 000美元)的赔偿金,并列举了尽管NAION被归类为极为罕见的副作用——在10,000名使用者中高达1人——但连接的初步证据。 The Danish Patient Compensation Association awarded 800,000 kroner ($123,000) to the patients, citing preliminary evidence of a connection despite NAION being classified as a very rare side effect—up to 1 in 10,000 users. 该决定是根据40多个申请中的5个经过评估的案件作出的,是第一批此类批准。 The decision, based on five assessed cases among over 40 applications, marks the first such approvals. 欧洲药品局证实了这一罕见的风险,并建议提出最新警告。 The European Medicines Agency confirmed the rare risk and recommended updated warnings. Novo Nordisk认为药品的好处胜过风险, 并更新了安全信息。 Novo Nordisk maintains the drugs’ benefits outweigh risks and has updated safety information. 如果长期残疾或收入损失得到确认,补偿可能会增加。 Compensation may increase if long-term disability or lost income is confirmed.